Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.

ABSTRACT:

Background

New bone-directed therapies, including denosumab, abaloparatide, and romosozumab, emerged during the past decade, and recent trends in use of these therapies are unknown.

Objective

To examine temporal trends in bone-directed therapies.

Design

An open cohort study in a US commercial insurance database, January 2009 to March 2020.

Participants/interventions

All-users of bone-directed therapies age >50 years, users with osteoporosis, users with malignancies, and patients with recent (within 180 days) fractures at key osteoporotic sites.

Main measures

The percentage of each cohort with prescription dispensing or medication administration claims for each bone-directed therapy during each quarter of the study period.

Key results

We analyzed 1

SUBMITTER: Cromer SJ 

PROVIDER: S-EPMC9198174 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature